BrainStorm Cell Therapeutics to Unveil Phase 3b NurOwn® Trial Design at MDA Clinical and Scientific Conference streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today.
Brainstorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request To FDA For Phase 3B Trial Of Nurown® In ALS menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
By Denny Jacob BrainStorm Cell Therapeutics shares rose 7.2% to 35 cents following a submitted special protocol assessment request to the Food and Drug.
NEW YORK, Feb. 13, 2024 /PRNewswire/ BrainStorm Cell Therapeutics Inc. , a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it will provide.